Press release article from our research archive:

Phase III Data on BEMA(TM) Fentanyl to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.(Clinical report)

RALEIGH, N.C. -- BioDelivery Sciences International, Inc. (Nasdaq:BDSI) and commercial partner, Meda Pharmaceuticals, today announced they will present results from Phase III clinical studies assessing the efficacy and safety of BEMA[TM] Fentanyl at a poster session on May 31, 2008, during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The presentation will feature data from two Phase III clinical studies assessing the efficacy and safety of BEMA[TM] Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid tolerant patients with cancer.

Patients on stable background opioid medication were enrolled in an efficacy study, ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!